CuraTeQ Biologics receives European marketing authorization for biosimilar Dazublys?

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorization from the European Commission for Dazublys?, its trastuzumab biosimilar version. Earlier in April 2025, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys?, recommending its marketing authorization. This is CuraTeQ's third biosimilar to be approved by EMA after the approval of Dyrupeg? in April 2025 and Zefylti? in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva? by the UK's MHRA in December 2024.

Powered by Capital Market - Live News